University of Hertfordshire

By the same authors

The Erectile Dysfunction and Statins (EDS) trial [ISRCTN66772971].

Research output: Contribution to conferenceAbstractpeer-review

Standard

The Erectile Dysfunction and Statins (EDS) trial [ISRCTN66772971]. / Kirby, Michael; Trivedi, Daksha; Wellsted, D.

2012. Abstract from British Society for Sexual Medicine, 15th Annual Scientific Meeting 2012, London, United Kingdom.

Research output: Contribution to conferenceAbstractpeer-review

Harvard

Kirby, M, Trivedi, D & Wellsted, D 2012, 'The Erectile Dysfunction and Statins (EDS) trial [ISRCTN66772971].', British Society for Sexual Medicine, 15th Annual Scientific Meeting 2012, London, United Kingdom, 27/01/12 - 27/01/12. <http://www.bssm.org.uk/meetings/ >

APA

Kirby, M., Trivedi, D., & Wellsted, D. (2012). The Erectile Dysfunction and Statins (EDS) trial [ISRCTN66772971].. Abstract from British Society for Sexual Medicine, 15th Annual Scientific Meeting 2012, London, United Kingdom. http://www.bssm.org.uk/meetings/

Vancouver

Kirby M, Trivedi D, Wellsted D. The Erectile Dysfunction and Statins (EDS) trial [ISRCTN66772971].. 2012. Abstract from British Society for Sexual Medicine, 15th Annual Scientific Meeting 2012, London, United Kingdom.

Author

Kirby, Michael ; Trivedi, Daksha ; Wellsted, D. / The Erectile Dysfunction and Statins (EDS) trial [ISRCTN66772971]. Abstract from British Society for Sexual Medicine, 15th Annual Scientific Meeting 2012, London, United Kingdom.

Bibtex

@conference{35528905bb32439399f08ecd69569e6c,
title = "The Erectile Dysfunction and Statins (EDS) trial [ISRCTN66772971].",
abstract = "We conducted a trial to establish whether, in men with untreated erectile dysfunction (ED) and untreated cardiovascular risk factors, lowering LDL cholesterol with simvastatin 40 mg improves ED as measured by the abridged International Index of Erectile Function (IIEF-5). Secondary outcomes: i) improves sexual health related quality of life (QOL); whether ii) improvement in erectile function correlates with a reduction in LDL cholesterol and/or improved endothelial function; and whether iii) treatment of ED with simvastatin is cost effective. 173 men were randomised to receive either 40 mg simvastatin or a placebo for six months. Outcomes: Baseline characteristics: The average age of the patients was 56.1 years, with BMI 27.7, testosterone 15.1 nmol/L, and 10 year CVD risk of 8.2%. The average IIEF score 13.5. 113 patients completed all the study measures, and a further 18 patients (N=131) completed the QoL measures despite withdrawing from the study. . Data is available for 117 patients. Main study outcomes : The improvement in IIEF due to Statin treatment is not statistically different to Placebo (1.28 versus 0.07, z=1.1, p=0.27). All patients with Severe ED at baseline show a larger change than patients with Mild/Moderate ED (1.8 and 0.08, z=8.5, p<0.001). There was a statistically larger improvement in MED QoL for men on Statin compared to Placebo (5% vs 2%, z=2.09, p=.04). There is an increase in reported Satisfaction over time (z=2.17, p=.03). Both 10 year CVD risk and LDLwas reduced. (CV risk, z=-3.67, p<.001; LDL, z=-5.46, p<0.001). Testosterone is unaffected by treatment (z=-.94), and Baseline Testosterone is not related to any of the study outcomes ( z=1.63, p=.1). The cost and QALY regression results indicate that simvastatin may potentially reduce costs in this group. There was no consistent change in the endothelial function. ",
keywords = "erectile dysfunction, statins, randomised controlled trial",
author = "Michael Kirby and Daksha Trivedi and D. Wellsted",
year = "2012",
language = "English",
note = "British Society for Sexual Medicine, 15th Annual Scientific Meeting 2012 ; Conference date: 27-01-2012 Through 27-01-2012",

}

RIS

TY - CONF

T1 - The Erectile Dysfunction and Statins (EDS) trial [ISRCTN66772971].

AU - Kirby, Michael

AU - Trivedi, Daksha

AU - Wellsted, D.

PY - 2012

Y1 - 2012

N2 - We conducted a trial to establish whether, in men with untreated erectile dysfunction (ED) and untreated cardiovascular risk factors, lowering LDL cholesterol with simvastatin 40 mg improves ED as measured by the abridged International Index of Erectile Function (IIEF-5). Secondary outcomes: i) improves sexual health related quality of life (QOL); whether ii) improvement in erectile function correlates with a reduction in LDL cholesterol and/or improved endothelial function; and whether iii) treatment of ED with simvastatin is cost effective. 173 men were randomised to receive either 40 mg simvastatin or a placebo for six months. Outcomes: Baseline characteristics: The average age of the patients was 56.1 years, with BMI 27.7, testosterone 15.1 nmol/L, and 10 year CVD risk of 8.2%. The average IIEF score 13.5. 113 patients completed all the study measures, and a further 18 patients (N=131) completed the QoL measures despite withdrawing from the study. . Data is available for 117 patients. Main study outcomes : The improvement in IIEF due to Statin treatment is not statistically different to Placebo (1.28 versus 0.07, z=1.1, p=0.27). All patients with Severe ED at baseline show a larger change than patients with Mild/Moderate ED (1.8 and 0.08, z=8.5, p<0.001). There was a statistically larger improvement in MED QoL for men on Statin compared to Placebo (5% vs 2%, z=2.09, p=.04). There is an increase in reported Satisfaction over time (z=2.17, p=.03). Both 10 year CVD risk and LDLwas reduced. (CV risk, z=-3.67, p<.001; LDL, z=-5.46, p<0.001). Testosterone is unaffected by treatment (z=-.94), and Baseline Testosterone is not related to any of the study outcomes ( z=1.63, p=.1). The cost and QALY regression results indicate that simvastatin may potentially reduce costs in this group. There was no consistent change in the endothelial function.

AB - We conducted a trial to establish whether, in men with untreated erectile dysfunction (ED) and untreated cardiovascular risk factors, lowering LDL cholesterol with simvastatin 40 mg improves ED as measured by the abridged International Index of Erectile Function (IIEF-5). Secondary outcomes: i) improves sexual health related quality of life (QOL); whether ii) improvement in erectile function correlates with a reduction in LDL cholesterol and/or improved endothelial function; and whether iii) treatment of ED with simvastatin is cost effective. 173 men were randomised to receive either 40 mg simvastatin or a placebo for six months. Outcomes: Baseline characteristics: The average age of the patients was 56.1 years, with BMI 27.7, testosterone 15.1 nmol/L, and 10 year CVD risk of 8.2%. The average IIEF score 13.5. 113 patients completed all the study measures, and a further 18 patients (N=131) completed the QoL measures despite withdrawing from the study. . Data is available for 117 patients. Main study outcomes : The improvement in IIEF due to Statin treatment is not statistically different to Placebo (1.28 versus 0.07, z=1.1, p=0.27). All patients with Severe ED at baseline show a larger change than patients with Mild/Moderate ED (1.8 and 0.08, z=8.5, p<0.001). There was a statistically larger improvement in MED QoL for men on Statin compared to Placebo (5% vs 2%, z=2.09, p=.04). There is an increase in reported Satisfaction over time (z=2.17, p=.03). Both 10 year CVD risk and LDLwas reduced. (CV risk, z=-3.67, p<.001; LDL, z=-5.46, p<0.001). Testosterone is unaffected by treatment (z=-.94), and Baseline Testosterone is not related to any of the study outcomes ( z=1.63, p=.1). The cost and QALY regression results indicate that simvastatin may potentially reduce costs in this group. There was no consistent change in the endothelial function.

KW - erectile dysfunction, statins, randomised controlled trial

M3 - Abstract

T2 - British Society for Sexual Medicine, 15th Annual Scientific Meeting 2012

Y2 - 27 January 2012 through 27 January 2012

ER -